Novartis announced today the early termination of the ALTITUDE trial, which was testing the effect of the direct renin inhibitor aliskiren (Rasilez, Tekturna) in type 2 diabetics at high risk for cardiovascular and renal events.
Afraid that grantees like DC would reap the benefit of these 19 years without fair compensation to authors, Congress included a termination right, allowing authors to take back the rights in their works before the extended period took effect.